Brief: Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast Cancer
16/04/2025 12:34
April 16 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL PHASE 2 SURVIVAL DATA BEATS LEADING STANDARD IN HR+ BREAST CANCER BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS MEDIAN OVERALL SURVIVAL IN HR+ MBC PATIENTS BRIACELL THERAPEUTICS CORP - BRIA-IMT SURVIVAL DATA IN TNBC PATIENTS COMPARABLE TO TRODELVY BRIACELL THERAPEUTICS CORP - NO BRIA-IMT RELATED DISCONTINUATIONS REPORTED TO DATE Source text: ID:nGNX1GCq2 Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study